← Leaderboards
Patrick A Burch
Mayo Clinic Coll Of Medicine, Rochester
$0
Attributed
$0
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$0 · 2
By mechanism
M01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Alex A Adjei$13,436,633
- Lieping Chen$19,852,609
- Charles Erlichman$15,466,165
- Neil E Kay$14,251,394
- Keith C Bible$4,335,431
Others in their field
Top investigators on “Antineoplastics”
- David Heimbrook · Leidos Biomedical Research, Inc.$245,744,647
- Leonard Freedman · Leidos Biomedical Research, Inc.$243,278,693
- Charles A Coltman · Southwest Oncology Group$134,454,243
- Gregory H Reaman · National Childhood Cancer Foundation$112,139,479
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,166,869
- Richard L Schilsky · University Of Chicago$90,728,118
Research focus
AntineoplasticsClinical ResearchClinical Trial Phase IDosageDrug Screening /EvaluationHuman SubjectHuman Therapy EvaluationNeoplasm /Cancer ChemotherapyMaleDoxorubicinNeoplasm /CancerProstate Specific AntigenProstate Neoplasms
Grant awards (6)
CS 682 ADMINISTERED ORALLY IN PATIENTS W/ MALIGNANT SOLID TUMORS$0
M01 · FY2002 · RR
TRIAL OF L-377202 ONCE WEEKLY FOR 3 WEEKS$0
M01 · FY2002 · RR
CS 682 ADMINISTERED ORALLY IN PATIENTS W/ MALIGNANT SOLID TUMORS$0
M01 · FY2001 · RR
TRIAL OF L-377202 ONCE WEEKLY FOR 3 WEEKS$0
M01 · FY2001 · RR
CS 682 ADMINISTERED ORALLY IN PATIENTS W/ MALIGNANT SOLID TUMORS$0
M01 · FY2000 · RR
TRIAL OF L-377202 ONCE WEEKLY FOR 3 WEEKS$0
M01 · FY2000 · RR